scholarly journals Efficacy of dual therapy in patients >65 years old with alanine transaminase flare during chronic hepatitis C genotype 2

2015 ◽  
Vol 9 (1) ◽  
pp. 82
Author(s):  
Elena Garlatti Costa ◽  
Michela Ghersetti ◽  
Silvia Grazioli ◽  
Pietro Casarin
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Dual Therapy ◽  
Alanine Transaminase ◽  
Genotype 2

scholarly journals THE ECONOMIC IMPACT OF TREATING CHRONIC HEPATITIS C

2019 ◽  
Vol 34 (4) ◽  
pp. 1153-1157
Author(s):  
Evgenija Nikolovska ◽  
Velo Markovski
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Dual Therapy ◽  
Pegylated Interferon ◽  
Economic Problem ◽  
Decompensated Cirrhosis ◽  
Healthy Population ◽  
Genotype 2 ◽  
Direct Acting

Hepatitis C is a viral infection of the liver. This infection is a global problem because over 180 million people worldwide have chronic hepatitis type C (about 3% of the world's population). The highest prevalence occurs among intravenous drug addicts (about 52%), the virus can be transmitted from mother to child during childbirth (4-8%), and further the virus is transmitted through medical interventions, piercing, tattooing. In the Republic of Macedonia in the period from 2011 to 2017, 511 newly infected with Hepatitis C from a total of 31 municipalities were registered. Among the healthy population in Macedonia, 0.4% were positive for HCV, while among the risk groups, 23% -52% were positive for HCV. In Macedonia, the groups at highest risk of HCV are: people who inject drugs (with a prevalence of 51.53%), people who are being treated with hemodialysis (with a prevalence of 37.91%), people who have become infected with HCV by transfusion (with a prevalence of 1,48%), people who have become HCV infected in other risky ways (with a prevalence of 9,08%). Hepatitis C virus is a serious health, but also an economic problem. Treatment of hepatitis C is expensive and therefore hardly accessible to people motivated to heal from hepatitis C. Тhe treatment of patients with chronic hepatitis C was performed with a combination of pegylated interferon alfa and ribavirin (dual therapy) for 24 or 48 weeks. Early detection of HCV infection is very important, because chronic hepatitis C is already a treatable disease, until the stage of decompensated cirrhosis and / or HCC. Disease control is successfully achieved by 30-60% with standard interferon, 40-70% depending on the genotype with pegylated interferon (in combination with ribavirin), and 40-90% with new direct-acting antivirals (DAAs). In addition, the benefit of treatment is that it reduces the risk of further spread of the virus. Treatment with the most recent direct-acting drugs (DAAs) started in 2011, lasts much shorter, 12 to 24 weeks, has the least risky effects and the highest percentage of negativity (up to 90%) but is not yet widely used (expensive in many countries not yet registered ). For example, sophosuvir is only regressed in some richer countries, and treatment with it costs about $ 84,000 ($ 1,000 per pill). In 2011, treatment with Copegus and Pegasus for 48 weeks of treatment, for patients under 75 kg, required a total of 1,215,974 MKD (44,831 MKD cost per one Copegus package and 15,993 MKD for a Pegasus injection). For patients over 75 kg the total cost is 1,305,636 MKD. For genotype 2 and 3 the total costs for all patients regardless of body weight were 563,156 MKD. Total costs in 2017 for Copegus and Pegasus for 48 weeks of treatment for patients with Hepatitis C genotype 1 and 4 in Macedonia cost 655,964 MKD, which means a 46% decrease compared to 2011.

Early prediction of sustained virological response at day 3 of treatment with albinterferon-α-2b in patients with genotype 2/3 chronic hepatitis C

2009 ◽  
Vol 29 (9) ◽  
pp. 1350-1355 ◽  
Author(s):  
Avidan U. Neumann ◽  
Vincent G. Bain ◽  
Eric M. Yoshida ◽  
Keyur Patel ◽  
Erik Pulkstenis ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Early Prediction ◽  
Genotype 2

High risk of aminotransferase flares in patients with chronic hepatitis C genotype 2

2002 ◽  
Vol 36 ◽  
pp. 245
Author(s):  
Maria Grazia Rumi ◽  
Francesca De Filippi ◽  
Carlo La Vecchia ◽  
Silvano Gallus ◽  
Roberta Soffredini ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
High Risk ◽  
Chronic Hepatitis C ◽  
Genotype 2

scholarly journals A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

Gut ◽  
2007 ◽  
Vol 56 (4) ◽  
pp. 553-559 ◽  
Author(s):  
M.-L. Yu ◽  
C.-Y. Dai ◽  
J.-F. Huang ◽  
N.-J. Hou ◽  
L.-P. Lee ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Randomised Study ◽  
Genotype 2 ◽  
Peginterferon And Ribavirin

scholarly journals Chronic hepatitis C virus infections in Brazilian patients: association with genotypes, clinical parameters and response to long term alpha interferon therapy

1999 ◽  
Vol 41 (3) ◽  
pp. 183-189 ◽  
Author(s):  
Leda BASSIT ◽  
Luiz C. DA SILVA ◽  
Gabriela RIBEIRO-DOS-SANTOS ◽  
Geert MAERTENS ◽  
Flair J. CARRILHO ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hcv Infection ◽  
Sustained Response ◽  
Response To Treatment ◽  
Recombinant Interferon ◽  
Genotype 2

The present study assessed the clinical significance of hepatitis C virus (HCV) genotypes and their influence on response to long term recombinant-interferon-alpha (r-IFN-<FONT FACE="Symbol">a</FONT>) therapy in Brazilian patients. One hundred and thirty samples from patients previously genotyped for the HCV and with histologically confirmed chronic hepatitis C (CH-C) were evaluated for clinical and epidemiological parameters (sex, age, time of HCV infection and transmission routes). No difference in disease activity, sex, age or mode and time of transmission were seen among patients infected with HCV types 1, 2 or 3. One hundred and thirteen of them were treated with 3 million units of r-IFN-<FONT FACE="Symbol">a</FONT>, 3 times a week for 12 months. Initial response (IR) was significantly better in patients with genotype 2 (100%) and 3 (46%) infections than in patients with genotype 1 (29%) (p < 0.005). Among subtypes, difference in IR was observed between 1b and 2 (p < 0.005), and between 1b and 3a (p < 0.05). Sustained response (SR) was observed in 12% for (sub)type 1a, 13% for 1b, 19% for 3a, and 40% for type 2; significant differences were found between 1b and 2 (p < 0.001), and between 1b and 3a (p < 0.05). Moreover, presence of cirrhosis was significantly associated with non response and response with relapse (p < 0.05). In conclusion, non-1 HCV genotype and lack of histological diagnosis of cirrhosis were the only baseline features associated with sustained response to treatment. These data indicate that HCV genotyping may have prognostic relevance in the responsiveness to r-IFN-<FONT FACE="Symbol">a</FONT> therapy in Brazilian patients with chronic HCV infection, as seen in other reports worldwide.

T1037 Response-Guided Therapy of Peginterferon Alpha 2B Plus Ribavirin for Chronic Hepatitis C with Genotype 2 and a High Viral Road As An Effective Method Optimizing Therapy Duration

2009 ◽  
Vol 136 (5) ◽  
pp. A-485-A-486
Author(s):  
Ken Sato ◽  
Katsuhiko Horiuchi ◽  
Atsushi Naganuma ◽  
Takashi Kosone ◽  
Kazuhisa Yuasa ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Genotype 2 ◽  
Guided Therapy
Sign in / Sign up

Export Citation Format

Share Document